Neil Brewis
Chief Executive Officer bei F-STAR THERAPEUTICS, INC.
Aktive Positionen von Neil Brewis
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
F-STAR THERAPEUTICS, INC. | Director/Board Member | 08.03.2023 | - |
Chief Executive Officer | - | - | |
Chief Tech/Sci/R&D Officer | 20.11.2020 | - | |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | 02.11.2015 | - |
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - | - |
Karriereverlauf von Neil Brewis
Ehemalige bekannte Positionen von Neil Brewis
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GSK PLC | Corporate Officer/Principal | 01.01.2007 | 01.10.2015 |
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01.01.2002 | 01.01.2007 |
SPRING BANK PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 20.11.2020 | - |
Ausbildung von Neil Brewis
University Of Dundee | Doctorate Degree |
University of Hertfordshire | Undergraduate Degree |
Statistik
International
Vereinigtes Königreich | 7 |
Vereinigte Staaten | 2 |
Österreich | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 4 |
Director/Board Member | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
GSK PLC | Health Technology |
Private Unternehmen | 5 |
---|---|
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Health Technology |
F-Star Therapeutics, Inc. (United States)
F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
F-star Therapeutics, Inc.
F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Neil Brewis
- Erfahrung